Diabetes Markedly Raises Sudden Cardiac Death Risk, With the Greatest Excess Hazard in Younger Adults

Section Structure

Highlights

Clinical Background

Study Design and Methods

Key Results

Clinical Interpretation

Strengths and Limitations

Implications for Practice and Research

Conclusion

Funding and Trial Registration

References

Highlights

In this nationwide Danish analysis of the entire 2010 population, both type 1 diabetes and type 2 diabetes were associated with substantially higher sudden cardiac death incidence than in the general population.

The excess relative risk was most pronounced at younger ages, reinforcing that sudden cardiac death in diabetes is not only a late-life complication linked to long-standing cardiovascular disease.

Sudden cardiac death contributed materially to reduced life expectancy, with average life-years lost of 14.2 years in type 1 diabetes and 7.9 years in type 2 diabetes, and an estimated 3.4 and 2.7 years of life expectancy reduction specifically attributable to sudden cardiac death.

The findings support a broader cardiovascular prevention agenda in diabetes that extends beyond atherosclerotic events and heart failure to arrhythmic death prevention.

Clinical Background

Diabetes mellitus has long been linked to excess cardiovascular mortality, but its relationship with sudden cardiac death has been more difficult to define precisely. Prior studies have suggested an elevated risk, yet many were limited by selected populations, incomplete adjudication of sudden death, or insufficient separation of type 1 diabetes from type 2 diabetes. That distinction matters clinically because the two conditions differ in age at onset, metabolic phenotype, burden of coronary disease, prevalence of autonomic neuropathy, insulin exposure, and arrhythmic substrates.

Sudden cardiac death is usually defined as an unexpected natural death from a presumed cardiac cause occurring within a short time period, often within 1 hour of symptom onset when witnessed, or within 24 hours of last being seen alive and well when unwitnessed. It is an especially important endpoint because it combines high lethality with limited opportunity for rescue. In diabetes, several biologically plausible pathways may increase susceptibility: accelerated coronary atherosclerosis, silent ischemia, diabetic cardiomyopathy, cardiac autonomic neuropathy, repolarization abnormalities, electrolyte disturbances, severe hypoglycemia, kidney disease, and structural remodeling associated with hypertension and obesity.

Against this backdrop, the Danish nationwide study by Skjelbred and colleagues addresses an important evidence gap. By evaluating the entire national population and using detailed death certificate review supplemented by discharge summaries and autopsy reports when available, the investigators aimed to produce more robust estimates of sudden cardiac death burden in both type 1 and type 2 diabetes. The study also moved beyond relative risk to quantify shortened life expectancy attributable to sudden cardiac death, a measure with stronger public health and policy relevance.

Study Design and Methods

This was a nationwide observational cohort study including the entire Danish population in 2010. The investigators identified sudden cardiac death cases through national death certificate data, discharge summaries, and autopsy reports where performed. This is a notable methodological strength because sudden cardiac death classification is vulnerable to misclassification when based solely on administrative coding.

The exposure groups were individuals with type 1 diabetes and type 2 diabetes. Although the abstract does not detail the exact classification algorithm, Danish registry-based studies commonly use linked prescription, hospital, and diagnostic data to distinguish diabetes subtypes. The comparator was the general population without the corresponding diabetes diagnosis.

The main analytic approach used Cox proportional hazards models to estimate the association between diabetes status and sudden cardiac death. Importantly, the authors report multivariable adjustment, indicating that diabetes remained independently associated with sudden cardiac death beyond measured confounders. The abstract does not list the full covariate set or hazard ratios with confidence intervals, so interpretation should remain aligned with the published summary rather than infer unreported estimates.

In addition to incidence and relative risk, the study estimated loss of life years for both type 1 and type 2 diabetes and calculated the reduction in life expectancy specifically attributable to sudden cardiac death. This adds a clinically intuitive dimension that is often missing from epidemiologic studies focused only on hazard ratios.

Key Results

Among 6,862 identified sudden cardiac death cases in Denmark during the study period, 97 occurred in individuals with type 1 diabetes and 1,149 in individuals with type 2 diabetes. These numbers immediately convey two complementary messages. First, sudden cardiac death occurs in both diabetes subtypes. Second, the absolute case burden is much larger in type 2 diabetes, reflecting its far greater population prevalence and its overlap with older age and conventional cardiovascular risk factors.

The incidence rates of sudden cardiac death were markedly elevated in both groups compared with the general population. For type 1 diabetes, the incidence rate was 3.7-fold higher. For type 2 diabetes, it was 6.5-fold higher. These are striking magnitudes, particularly because they derive from an unselected national population rather than a specialized referral cohort.

After multivariable adjustment, both type 1 diabetes and type 2 diabetes remained independently associated with sudden cardiac death. The persistence of association after adjustment suggests that diabetes is not acting merely as a proxy for coexisting cardiovascular disease or demographic differences. Instead, it appears to contribute additional risk that may reflect a complex combination of structural heart disease, arrhythmic vulnerability, metabolic instability, and microvascular or autonomic complications.

One of the most clinically important observations was age dependence. The greatest risk difference was observed in younger individuals with diabetes, and the relative excess risk diminished with increasing age. This pattern has several implications. In older adults, sudden cardiac death risk is already higher in the background population because of age-related cardiovascular disease, so the relative contribution of diabetes may appear smaller. In contrast, when younger adults with diabetes experience a large relative increase in risk, it signals premature cardiovascular vulnerability and highlights an important prevention gap. From a public health perspective, younger-onset excess risk is especially consequential because more potential years of life are lost.

The life expectancy analysis reinforces that point. Average life-years lost were 14.2 years in type 1 diabetes and 7.9 years in type 2 diabetes. These figures likely reflect both earlier age at death and the broader mortality profile associated with each condition. The larger life-years lost estimate in type 1 diabetes is particularly compelling. Although the absolute number of sudden cardiac death cases was smaller than in type 2 diabetes, affected individuals lost substantially more years of life on average.

When the investigators focused specifically on life expectancy reduction attributable to sudden cardiac death, they estimated a loss of 3.4 years for type 1 diabetes and 2.7 years for type 2 diabetes. This is an important conceptual distinction. It suggests that sudden cardiac death is not simply one component of excess mortality in diabetes; it is a major and quantifiable contributor to reduced survival.

Because the abstract does not report subgroup data by sex, duration of diabetes, kidney disease status, coronary disease, insulin therapy, or use of cardioprotective medications, caution is warranted in overextending the results to mechanistic or treatment-specific conclusions. Even so, the headline findings are clear: sudden cardiac death burden is substantially increased in both type 1 and type 2 diabetes, and this excess burden translates into meaningful loss of life expectancy.

Clinical Interpretation

For clinicians, the study broadens the usual cardiovascular frame in diabetes care. Current practice appropriately emphasizes prevention of myocardial infarction, stroke, heart failure, and chronic kidney disease. However, these data suggest that sudden cardiac death deserves more explicit attention within diabetes risk assessment and prevention strategies.

In type 2 diabetes, elevated sudden cardiac death risk is likely driven in large part by the convergence of established arrhythmic substrates: ischemic heart disease, left ventricular dysfunction, obesity, sleep apnea, chronic kidney disease, and autonomic imbalance. The 6.5-fold higher incidence rate compared with the general population underscores how deeply arrhythmic risk may be embedded in the broader cardiometabolic syndrome.

In type 1 diabetes, the mechanisms may be more heterogeneous. Premature coronary disease remains important, but severe hypoglycemia, autonomic neuropathy, QT interval abnormalities, and inflammatory or fibrotic myocardial changes may play a comparatively larger role in some patients. The marked life-years lost in type 1 diabetes is a reminder that sudden death in this group often occurs before old age and therefore carries a disproportionate human and societal burden.

The age interaction is especially noteworthy. Younger adults with diabetes may not always be perceived as candidates for intensive cardiovascular rhythm-related risk stratification unless they already have overt heart disease. This study suggests that the absence of advanced age should not be equated with low sudden death risk in diabetes. Rather, younger age may amplify the relative excess hazard.

How should this change practice today? The study does not provide a direct intervention algorithm, but it supports several practical priorities. First, optimize established cardiovascular risk reduction early and consistently: lipid lowering, blood pressure control, smoking cessation, renal protection, and evidence-based glucose management. Second, identify structural heart disease promptly, especially left ventricular dysfunction and ischemic heart disease. Third, pay closer attention to autonomic symptoms, severe hypoglycemia, syncope, palpitations, and family history of sudden death. Fourth, in type 2 diabetes, use therapies with proven cardiovascular benefit where appropriate, including sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists, recognizing that their direct effect on sudden cardiac death remains less certain than their effect on heart failure and atherosclerotic outcomes.

For cardiologists, the findings argue for closer integration with diabetes care, particularly in patients with long diabetes duration, albuminuria, chronic kidney disease, neuropathy, prior cardiovascular events, or unexplained symptoms suggestive of arrhythmia. For endocrinologists and internists, the study is a reminder that cardiovascular risk in diabetes includes electrically mediated death, not only progressive vascular disease.

Strengths and Limitations

The study has several clear strengths. Its nationwide design reduces referral and selection bias. Inclusion of the entire Danish population enhances representativeness. Ascertainment of sudden cardiac death through detailed death certificate review supplemented by discharge summaries and autopsy information is more rigorous than many registry-only analyses. Distinguishing type 1 from type 2 diabetes is also highly valuable because these conditions are often pooled despite different risk architectures.

The life expectancy analysis is another important strength. Relative risks can appear abstract in routine practice, whereas years of life lost are easier for clinicians, patients, and policy makers to understand. Demonstrating that sudden cardiac death accounts for multiple years of reduced life expectancy gives the findings practical weight.

Several limitations should also be recognized. As an observational study, residual confounding cannot be excluded. The abstract does not specify the diabetes classification method, covariates used for adjustment, duration of diabetes, glycemic control, presence of severe hypoglycemia, kidney disease stage, left ventricular ejection fraction, or medication use. These variables could help clarify which components of diabetes confer the greatest arrhythmic hazard. Misclassification of sudden cardiac death is always possible, particularly in unwitnessed deaths, even with detailed review. Generalizability may also be shaped by Denmark’s healthcare system, population characteristics, and registry quality, which may differ from those of more ethnically diverse or less integrated health systems.

Finally, the study is highly informative for burden and association, but it does not establish which preventive strategies most effectively reduce sudden cardiac death specifically in diabetes. That remains a major research need.

Implications for Practice and Research

The main translational message is that diabetes should be viewed as a condition associated with excess sudden cardiac death risk across the age spectrum, not solely as a chronic vascular disease of later life. This has implications for risk communication, preventive care pathways, and research prioritization.

Future work should aim to refine risk stratification beyond diabetes status alone. Important candidates include albuminuria, kidney function, autonomic neuropathy, prior severe hypoglycemia, coronary calcium or ischemic burden, left ventricular function, ECG markers such as QT prolongation, and perhaps wearable-derived arrhythmia signals. Whether diabetes-specific sudden cardiac death prediction models can improve outcomes remains unknown but increasingly plausible in the era of integrated electronic health data.

Interventional questions are equally important. Which therapies reduce sudden cardiac death risk most effectively in diabetes: aggressive ischemia prevention, heart failure-directed therapy, autonomic dysfunction management, hypoglycemia minimization, or device therapy in selected structural heart disease? The answer will likely differ between type 1 and type 2 diabetes. Mechanistic studies separating ischemic from nonischemic and bradyarrhythmic from tachyarrhythmic pathways are also needed.

At the policy level, the data support sustained investment in earlier cardiovascular prevention in diabetes, particularly for younger adults who may otherwise be undertreated because of lower short-term absolute event risk despite high lifetime risk.

Conclusion

This Danish nationwide study provides some of the strongest population-level evidence to date that both type 1 and type 2 diabetes are associated with markedly elevated sudden cardiac death incidence. The excess relative risk is greatest in younger people with diabetes and remains independently associated after multivariable adjustment. Beyond relative risk, sudden cardiac death contributes materially to reduced survival, accounting for an estimated 3.4 years of life expectancy loss in type 1 diabetes and 2.7 years in type 2 diabetes.

For clinicians, the findings sharpen the case for comprehensive cardiovascular prevention in diabetes and suggest that arrhythmic death deserves more explicit attention in routine care and future guideline development. For researchers, the study highlights the urgent need to identify the phenotypes, mechanisms, and interventions that can most effectively reduce sudden cardiac death in diabetes.

Funding and Trial Registration

The abstract provided does not report funding details. ClinicalTrials.gov registration is not applicable for this nationwide observational registry study unless otherwise specified in the full text.

References

1. Skjelbred T, Warming PE, Behr ER, Køber L, Pedersen-Bjergaard U, Winkel BG, Lynge TH, Tfelt-Hansen J. Diabetes and sudden cardiac death: a Danish nationwide study. European Heart Journal. 2026 Jun 2;47(21):2644-2656. PMID: 41338249.

2. Marx N, Federici M, Schütt K, Müller-Wieland D, Ajjan RA, Antunes MJ, et al. 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes. European Heart Journal. 2023;44(39):4043-4140.

3. Priori SG, Blomström-Lundqvist C, Mazzanti A, Blom N, Borggrefe M, Camm J, et al. 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. European Heart Journal. 2015;36(41):2793-2867.